Paul Matteis

Stifel | Healthcare

Paul Matteis is an analyst from Stifel specializing in the Healthcare sector. Ranked #548 out of 4773 analysts, they have issued 34 stock ratings with a success rate of 87.57% and an average return of 43.91%.

Paul Matteis has a well-established track record, with 34 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 87.57% and an average return of 43.91%, underscoring their expertise and ability to identify winning opportunities for investors.

#548

Out of 4773

34

Total Ratings

+87.57%

Success Rate

+43.91%

Average Return

Recent Ratings Analysis

NBIX

Jul 31, 2026

Target

$215.00

Current

$156.22

Performance

-6.34%

Paul Matteis rated NBIX as Buy on Jul 31, 2026, setting a price target of 215. The stock has underperformed, dropping 6.34% despite the bullish target of 215.

ALNY

Jul 31, 2026

Target

$318.00

Current

$248.68

Performance

21.00%

On Jul 31, 2026, ALNY was given a Buy rating by Paul Matteis, with a target price of 318. The stock rallied 21.00% after the rating, narrowing the gap to the target of 318 and validating the bullish stance.

ACAD

Jul 21, 2026

Target

$25.00

Current

$27.83

Performance

9.44%

ACAD received a Hold rating from Paul Matteis on Jul 21, 2026, aiming for 25. Investors saw gains of 9.44% that the cautious stance didn’t fully capture.

ALKS

Jul 20, 2026

Target

$63.00

Current

$45.97

Performance

-11.12%

On Jul 20, 2026, Paul Matteis published a Buy outlook on ALKS, with a target of 63. Market action contradicted the Buy thesis, as shares slipped to 45.97.

CMPS

Jul 08, 2026

Target

$21.00

Current

$14.35

Performance

2.72%

Paul Matteis on Jul 08, 2026 assigned CMPS a Buy rating, with a price target of 21. The recommendation remains pending validation as shares consolidate around 14.35.

DFTX

Jul 08, 2026

Target

$60.00

Current

$38.89

Performance

-14.19%

On Jul 08, 2026, Paul Matteis reaffirmed DFTX with a Buy rating, targeting 60. Shares slid 14.19% despite the recommendation, highlighting downside risks.

MPLT

Jun 02, 2026

Target

$36.00

Current

$13.00

Performance

—

MPLT was rated Buy by Paul Matteis on Jun 02, 2026, with a price objective of 36. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

SPTX

May 26, 2026

Target

$30.00

Current

$23.34

Performance

29.59%

On May 26, 2026, Paul Matteis initiated coverage on SPTX with a Buy rating and target of 30. The stock’s climb of 29.59% since the call highlights the foresight in the rating.

SION

May 18, 2026

Target

$55.00

Current

$7.85

Performance

-79.99%

Paul Matteis issued a Buy recommendation for SION on May 18, 2026, price target set at 55. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

IMUX

Apr 17, 2026

Target

$2.50

Current

$11.42

Performance

14.20%

On Apr 17, 2026, IMUX was evaluated by Paul Matteis, who gave a Buy rating and target of 2.5. This case illustrates how a timely bullish rating can translate into tangible gains of 14.20%.

LBRX

Mar 27, 2026

Target

$40.00

Current

$44.63

Performance

87.21%

Paul Matteis rated LBRX as Buy on Mar 27, 2026, setting a price target of 40. The call has proven timely, with shares rising 87.21% toward the price target of 40.

KALV

Mar 26, 2026

Target

$42.00

Current

$27.00

Performance

—

On Mar 26, 2026, KALV was given a Buy rating by Paul Matteis, with a target price of 42. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

IONS

Feb 26, 2026

Target

$77.00

Current

$54.21

Performance

-32.74%

IONS received a Hold rating from Paul Matteis on Feb 26, 2026, aiming for 77. The Hold stance proved prudent, with the market softening by 32.74%.

VRTX

Feb 13, 2026

Target

$466.00

Current

$515.44

Performance

4.88%

On Feb 13, 2026, Paul Matteis published a Hold outlook on VRTX, with a target of 466. Sideways action left the Hold view intact, with no major move since 515.44.

QURE

Dec 11, 2025

Target

$50.00

Current

$44.51

Performance

125.37%

Paul Matteis on Dec 11, 2025 assigned QURE a Buy rating, with a price target of 50. The Buy call aligned well with market performance, producing a gain of 125.37%.

DYN

Dec 11, 2025

Target

$39.00

Current

$18.21

Performance

-6.23%

On Dec 11, 2025, Paul Matteis reaffirmed DYN with a Buy rating, targeting 39. Shares slid 6.23% despite the recommendation, highlighting downside risks.

NMRA

Nov 17, 2025

Target

$3.00

Current

$1.04

Performance

-59.85%

NMRA was rated Hold by Paul Matteis on Nov 17, 2025, with a price objective of 3. Investors who stayed cautious avoided some of the 59.85% decline.

BMRN

Nov 06, 2025

Target

$61.00

Current

$65.68

Performance

26.70%

On Nov 06, 2025, Paul Matteis initiated coverage on BMRN with a Hold rating and target of 61. The Hold stance underestimated the stock’s strength as it gained 26.70%.

BIIB

Nov 06, 2025

Target

$202.00

Current

$217.15

Performance

38.54%

Paul Matteis issued a Buy recommendation for BIIB on Nov 06, 2025, price target set at 202. Investors following the Buy call captured upside momentum, with shares now at 217.15.

PEPG

Sep 25, 2025

Target

$12.00

Current

$2.98

Performance

-49.32%

On Sep 25, 2025, PEPG was evaluated by Paul Matteis, who gave a Buy rating and target of 12. Investors saw limited payoff as shares fell short of the 12 target.

RYTM

May 29, 2025

Target

$94.00

Current

$104.71

Performance

69.21%

Paul Matteis rated RYTM as Buy on May 29, 2025, setting a price target of 94. The call has proven timely, with shares rising 69.21% toward the price target of 94.

GHRS

Feb 27, 2025

Target

$32.00

Current

$27.20

Performance

155.40%

On Feb 27, 2025, GHRS was given a Buy rating by Paul Matteis, with a target price of 32. The stock rallied 155.40% after the rating, narrowing the gap to the target of 32 and validating the bullish stance.

ALEC

Dec 16, 2024

Target

$4.00

Current

$2.14

Performance

8.08%

ALEC received a Hold rating from Paul Matteis on Dec 16, 2024, aiming for 4. Investors saw gains of 8.08% that the cautious stance didn’t fully capture.

DNLI

Dec 16, 2024

Target

$37.00

Current

$21.09

Performance

-9.45%

On Dec 16, 2024, Paul Matteis published a Buy outlook on DNLI, with a target of 37. Market action contradicted the Buy thesis, as shares slipped to 21.09.

SAGE

Dec 16, 2024

Target

$6.00

Current

$8.68

Performance

62.24%

Paul Matteis on Dec 16, 2024 assigned SAGE a Hold rating, with a price target of 6. Shares outperformed expectations, climbing 62.24% despite the neutral view.

RAPP

Jul 02, 2024

Target

$35.00

Current

$43.62

Performance

74.41%

On Jul 02, 2024, Paul Matteis reaffirmed RAPP with a Buy rating, targeting 35. The recommendation was supported by strong follow-through as the stock rose from 43.62 to 43.62.

Frequency Asked Questions

Who is Paul Matteis?

Paul Matteis is an analyst from Stifel specializing in the Healthcare sector.

What is Paul Matteis's success rate?

Paul Matteis currently has a success rate of +87.57%.

How many ratings has Paul Matteis issued?

Paul Matteis has issued 34 stock ratings so far.

What is the average return of Paul Matteis's calls?

Their stock ratings have generated an average return of +43.91%.

What is Paul Matteis's ranking?

Paul Matteis is ranked #548 out of 4773 analysts.

What types of ratings does Paul Matteis give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Paul Matteis?

You can follow Paul Matteis by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Paul Matteis?

Their latest rating was a Buy on NBIX issued on 2026-07-31.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep